New cell addback could shield kids from deadly infections after transplant

NCT ID NCT03810196

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This study tests whether giving children with leukemia a special type of donor immune cell (CD45RA-depleted) after a stem cell transplant can help their immune system recover faster and lower the risk of serious viral or fungal infections. The trial enrolls 50 children under 25 who are at high risk for infections after transplant. The approach aims to balance preventing graft vs. host disease while boosting infection-fighting ability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CD45RA-depleted donor immune cells
What this could lead to
If it works, this could lower the risk of life-threatening infections after a stem cell transplant for children with leukemia.
What could go wrong
This is an early, small trial (50 participants) testing a complex cell-processing procedure. It may not reduce infections or GVHD as hoped, and there are risks of immune reactions or treatment failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.